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EVIDENCE BASED NEURO-ONCOLOGY
Utility of Tranexamic acid to minimize blood loss in brain tumour surgery
Syed Sarmad Bukhari, Muhammad Shahzad Shamim

Abstract
Tranexamic acid is emerging as a useful option for a
number of clinical indications by virtue of its antifibrinolytic properties that allow better haemostasis and
lesser blood loss. Herein, the authors have attempted to
summarize the existing evidence on the possible role of
tranexamic acid in brain tumour surgeries.
Keywords: Tranexamic acid, brain tumor, coagulation,
hemostasis.

Introduction
Resection of brain tumours can be encountered with
significant haemorrhage that may affect complete
resection and puts the patient at risk. This is especially
true for certain highly vascular tumours such as a
significant
proportion
of
meningiomas,
haemangiopericytomas and haemangioblastomas.
With the advent of stereotactic technology, the risk of
intraparenchymal haemorrhage following needle
biopsy is also of concern especially in deep seated areas
like the brainstem.1,2 Anaemia and poor haemostasis
are both in themselves associated with poor outcomes
in neurosurgery. The general practice in surgical neurooncology is to optimize a patient’s haemostatic profile
prior to surgery and have blood available for
transfusion if the need arises. In Pakistan, this raises a
financial problem of cross matching blood that will
never be used, a financial burden for the majority of the
population. Transfusion of blood also comes with its
attendant risks.3,4 Current practice does not include
prophylactic use of a pharmaceutical means to reduce
blood loss. In this review, we examine the data on the
use of tranexamic acid (TXA) in patients undergoing
brain tumour resection in terms of volume of blood loss
and any effect on outcomes.

Review of Evidence
Tranexamic acid (TXA) is an anti-fibrinolytic that enjoys
wide acceptance as a safe and effective means of
preventing excessive blood loss in both elective and
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emergency surgery. Its use has demonstrable effects in
reducing blood loss and improvement of outcomes.
CRASH II, a randomized controlled trial and economic
evaluation of the effects of TXA on death, vascular
occlusive events and transfusion requirement in
bleeding trauma patients, showed that early
administration of TXA reduced the risk of death in
bleeding trauma patients. However, there was always a
question of the risk of intravascular thrombotic
complications and seizures due to GABA antagonism
from the administration of TXA in patients with head
injury or those undergoing neurosurgical interventions,
which can be devastating.5 CRASH III, that looked at the
effects of TXA on death, disability, vascular occlusive
events and other morbidities in patients with acute
traumatic brain injury, showed that this risk was no
different from placebo and remained incredibly low.6
Vlu et al., published a case control study on the back of
the CRASH II data, which examined the effect of TXA on
haemostasis in patients undergoing brain tumour
removal by measuring APPT, PT index, TT, fibrinogen,
ATIII activity, factor XII-derived fibrinolysis,
spontaneous euglobulin lysis at four points in time after
the induction of anaesthesia, before Tranexam
injection, 30 minutes after Tranexam injection, on the
next day after the surgery. Blood from jugular and
peripheral veins was analyzed simultaneously.
According to their data, which was not publicly
available at the time of writing this review, TXA caused
a significant decrease in fibrinolytic activity and
decreased duration of time required to achieve
haemostasis and visual inspection of bleeding from the
wound. We believe their study design can be improved,
although they did report a decrease in wound drain
output.7 Beynon et al., have published an interesting
case report of a patient with coagulopathy with
uncertain pathology who needed a stereotactic
brainstem biopsy. The authors were able to perform it
safely by administering TXA and desmopressin without
a verifiable diagnosis for her coagulopathy.2 A 2011
report by Bharat et al., states that TXA does not have
widespread use in neurosurgery, but they found it
useful in an anecdotal report in which TXA
administration
arrested
severe
continuous
haemorrhage in a child with choroid plexus papilloma.
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An example of a skull base meningioma that could be a good candidate to use pre-operative TXA. This is a large tumour at a difficult location
Figure-A: MRI brain with contrast showing an intensely enhancing sphenoid wing meningioma.
Figure-B: CT angiogram brain demonstrating the highly vascular interior of the tumour. In the absence of angioembolization, surgery of this tumour will result in difficult haemostasis
and significant blood loss.

This was preceded by maximum standard efforts to
secure haemostasis.8 Phi et al., have described two
cases of infants who underwent surgery to remove a
similar tumour (choroid plexus papilloma) and in their
experience, TXA administration was associated with
blood loss that was less than 20% of the child’s total
circulating blood volume. When compared to another
similar case in which TXA was not used blood loss was
more than 100% of the total circulating blood volume.9

not significantly lower in the TXA group despite a lower
trend (p = 0.07). The number of patients who received a
transfusion was similar in both groups.11 Nilsson et al.,
studied the coagulation changes that occur
perioperatively in 40 patients undergoing neurosurgery
with hydroxyethylstarch (HES) as fluid therapy. Their
findings of mostly unaltered coagulation profile do not
support the routine use of TXA in patients undergoing
elective neurosurgery.12

The most useful evidence for the use of TXA in brain
tumour surgery comes from its use in meningioma and
complex skull base surgery. Mebel et al., performed a
retrospective cohort study to compare the rate of
perioperative transfusion between patients who did
and did not receive TXA during resection of complex
skull base tumours. The majority of these tumours were
acoustic neuromas and meningiomas. They concluded
that routine use of TXA reduces the risk of perioperative
transfusion in this group of patients and is an
independent determinant (adjusted OR 0.15–0.65
[p value = 0.002]).10 Hooda et al., published the first RCT
for the use of TXA in intracranial meningioma surgery.
They concluded that there was a 27% reduction in
estimated blood loss with the use of TXA (p <0.05).
However, the risk of requiring a blood transfusion was

Conclusion
We believe there is good evidence to suggest that TXA
may be used prophylactically in intracranial
meningioma surgery to reduce absolute blood loss but
the risk of transfusion may not be significantly reduced.
In paediatric highly vascular tumours such as choroid
plexus papilloma,its use may be warranted considering
the favourable side effect profile although the notion is
based entirely on anecdotal reports.
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